HC Wainwright Forecasts 89BIO's Q3 Earnings (NASDAQ:ETNB)

Key Points

• HC Wainwright predicts 89BIO will report a Q3 2025 earnings per share (EPS) of ($0.50), maintaining a "Buy" rating with a price target of $32.00.
• 89BIO missed its previous earnings estimate for Q2 2025, reporting an EPS of ($0.71) compared to the anticipated ($0.49).
• The stock has a market capitalization of $1.32 billion and has experienced a 1-year low of $4.16 and a high of $11.84.

89BIO (NASDAQ:ETNB - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for 89BIO in a report issued on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.50) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for 89BIO's current full-year earnings is ($3.19) per share. HC Wainwright also issued estimates for 89BIO's Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.22) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.31) EPS, FY2027 earnings at ($2.03) EPS, FY2028 earnings at ($1.55) EPS and FY2029 earnings at ($0.35) EPS.

89BIO (NASDAQ:ETNB - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.22). During the same period in the prior year, the business earned ($0.48) earnings per share.

Other equities analysts have also recently issued reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of 89BIO in a report on Saturday, August 30th. Royal Bank Of Canada reduced their price target on 89BIO from $12.00 to $11.00 and set a "sector perform" rating for the company in a report on Friday, August 8th. Finally, Bank of America dropped their price target on 89BIO from $30.00 to $29.00 and set a "buy" rating on the stock in a research report on Monday, August 25th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $28.00.

89BIO Stock Performance

Shares of ETNB stock traded down $0.58 during midday trading on Monday, hitting $8.07. The company had a trading volume of 717,738 shares, compared to its average volume of 1,340,342. The company has a debt-to-equity ratio of 0.07, a current ratio of 15.19 and a quick ratio of 15.19. 89BIO has a 52-week low of $4.16 and a 52-week high of $11.84. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -2.24 and a beta of 1.27. The company's 50 day simple moving average is $9.49 and its 200 day simple moving average is $8.73.

Insider Activity

In related news, insider Quoc Le-Nguyen sold 10,461 shares of the company's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $11.02, for a total value of $115,280.22. Following the completion of the transaction, the insider directly owned 309,364 shares of the company's stock, valued at approximately $3,409,191.28. This represents a 3.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ETNB. Dimensional Fund Advisors LP acquired a new stake in 89BIO in the fourth quarter valued at approximately $2,676,000. Hsbc Holdings PLC purchased a new stake in 89BIO in the 4th quarter valued at about $87,000. Price T Rowe Associates Inc. MD increased its stake in 89BIO by 11.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 47,292 shares of the company's stock valued at $370,000 after buying an additional 4,976 shares during the last quarter. Northern Trust Corp grew its position in shares of 89BIO by 7.6% during the 4th quarter. Northern Trust Corp now owns 854,787 shares of the company's stock valued at $6,684,000 after acquiring an additional 60,075 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in 89BIO by 107.7% in the 4th quarter. Ameriprise Financial Inc. now owns 28,230 shares of the company's stock worth $221,000 after buying an additional 14,641 shares during the period.

89BIO Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.